Allogene Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Allogene Therapeutics, Inc. (ALLO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $57.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Allogene Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $57.00M, a 26.11% increase from fiscal 2024.
- Allogene Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $45.20M, a 43.57% decline from fiscal 2023.
- Allogene Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $80.10M, a 25.97% decline from fiscal 2022.
- Allogene Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $108.20M, a 279.65% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $57.00M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $45.20M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $80.10M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $108.20M 10-K/A · filed 2024-03-14 | $99.90M 10-K · filed 2023-02-28 |
| 2021-12-31 | $28.50M 10-K/A · filed 2024-03-14 | $52.30M 10-K · filed 2022-02-23 |
| 2020-12-31 | $91.10M 10-K/A · filed 2024-03-14 | $72.50M 10-K · filed 2022-02-23 |
| 2019-12-31 | $50.00M 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |